Perrigo Company plc Intangible Assets, Net (Excluding Goodwill)
Perrigo Company plc (PRGO) had Intangible Assets, Net (Excluding Goodwill) of $4.55 billion as of 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2026-08-05
- 2026-06-27: Intangible Assets, Net (Excluding Goodwill) $4.55B.
- 2026-03-28: Intangible Assets, Net (Excluding Goodwill) $4.58B.
- 2025-12-31: Intangible Assets, Net (Excluding Goodwill) $4.76B.
- 2025-09-27: Intangible Assets, Net (Excluding Goodwill) $4.74B.
| Period end | Intangible Assets, Net (Excluding Goodwill) | Intangible Assets, Net (Excluding Goodwill) as first filed |
|---|---|---|
| 2026-06-27 | $4.55B 10-Q · filed 2026-08-05 | |
| 2026-03-28 | $4.58B 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $4.76B 10-Q · filed 2026-08-05 | |
| 2025-09-27 | $4.74B 10-Q · filed 2025-11-05 | |
| 2025-06-28 | $4.94B 10-Q · filed 2025-08-06 | |
| 2025-03-29 | $4.66B 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $4.50B 10-K · filed 2026-02-26 | |
| 2024-09-28 | $4.81B 10-Q · filed 2024-11-06 | |
| 2024-06-29 | $4.71B 10-Q · filed 2024-08-02 | |
| 2024-03-30 | $4.92B 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $5.00B 10-K · filed 2025-02-28 | |
| 2023-09-30 | $4.85B 10-Q · filed 2023-11-07 | |
| 2023-07-01 | $4.96B 10-Q · filed 2023-08-08 | |
| 2023-04-01 | $4.94B 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $5.01B 10-K · filed 2024-02-27 | |
| 2022-10-01 | $4.62B 10-Q · filed 2022-11-08 | |
| 2022-07-02 | $4.84B 10-Q · filed 2022-08-09 | |
| 2022-04-02 | $3.60B 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $3.68B 10-K · filed 2023-02-28 | |
| 2021-10-02 | $3.73B 10-Q · filed 2021-11-12 | |
| 2021-07-03 | $3.79B 10-Q · filed 2021-08-11 | |
| 2021-04-03 | $3.79B 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $3.89B 10-K · filed 2022-03-01 | $5.03B 10-K · filed 2021-03-01 |
| 2020-09-26 | $4.82B 10-Q · filed 2020-11-05 | |
| 2020-06-27 | $4.73B 10-Q · filed 2020-08-05 | |
| 2020-03-28 | $4.75B 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $4.75B 10-K · filed 2021-03-01 | |
| 2019-09-28 | $4.63B 10-Q · filed 2019-11-06 | |
| 2019-06-29 | $4.36B 10-Q · filed 2019-08-08 | |
| 2019-03-30 | $4.38B 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $4.43B 10-K · filed 2020-02-27 | |
| 2018-09-29 | $4.47B 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $4.68B 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $4.82B 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $4.75B 10-K · filed 2019-02-27 | |
| 2017-09-30 | $4.72B 10-Q · filed 2017-11-09 | |
| 2017-07-01 | $4.68B 10-Q · filed 2017-08-10 | |
| 2017-04-01 | $4.56B 10-Q · filed 2017-05-30 | |
| 2016-12-31 | $4.53B 10-K · filed 2018-03-01 | |
| 2016-10-01 | $5.12B 10-Q/A · filed 2017-05-23 | $10.93B 10-Q · filed 2016-11-10 |
| 2016-07-02 | $5.86B 10-Q/A · filed 2017-05-22 | $11.67B 10-Q · filed 2016-08-10 |
| 2016-04-02 | $5.95B 10-Q/A · filed 2017-05-22 | $11.76B 10-Q · filed 2016-05-16 |
| 2015-12-31 | $5.62B 10-K · filed 2018-03-01 | $11.43B 10-KT · filed 2016-02-25 |
| 2015-09-26 | $11.85B 10-Q · filed 2015-11-02 | |
| 2015-06-27 | $5.62B 10-K · filed 2017-05-22 | $11.42B 10-K · filed 2015-08-13 |
| 2015-03-28 | $7.50B 10-Q · filed 2015-04-29 | |
| 2014-12-27 | $7.50B 10-Q · filed 2015-02-05 | |
| 2014-09-27 | $7.44B 8-K · filed 2014-11-20 | |
| 2014-06-28 | $7.46B 10-KT · filed 2016-02-25 | |
| 2013-06-29 | $1.56B 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |